share_log

Insider Selling: Metacrine, Inc. (NASDAQ:MTCR) CEO Sells $156,048.05 in Stock

Insider Selling: Metacrine, Inc. (NASDAQ:MTCR) CEO Sells $156,048.05 in Stock

內幕銷售:美特克林公司(納斯達克:MTCR)首席執行官出售 156,048.05 美元的股票
Financial News Live ·  2023/01/30 17:51

Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 380,605 shares of the company's stock in a transaction that occurred on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total value of $156,048.05. Following the completion of the sale, the chief executive officer now owns 541,905 shares of the company's stock, valued at $222,181.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

梅塔克林公司(NASDAQ:MTCR-獲取評級)首席執行官普雷斯頓·克拉森在 1 月 26 日(星期四)發生的交易中出售了該公司股票的 380,605 股。該股票以 0.41 美元的平均價格出售,總價值 156,048.05 美元。出售完成後,首席執行官現擁有該公司股份的 541,905 股,價值為 222,181.05 元。該交易在向證券交易委員會提交的文件中披露,該文件可通過以下方式獲得 證券交易所網站

Metacrine Stock Performance

甲基林股票表現

MTCR opened at $0.48 on Monday. The company has a market capitalization of $20.44 million, a price-to-earnings ratio of -0.47 and a beta of -0.92. The company has a debt-to-equity ratio of 0.34, a current ratio of 12.15 and a quick ratio of 12.15. Metacrine, Inc. has a 1-year low of $0.30 and a 1-year high of $0.68. The business has a 50 day moving average price of $0.43 and a two-hundred day moving average price of $0.45.

MTCR 星期一以 0.48 美元開盤。該公司的市值為 20.44 萬美元,價格與收益比為 -0.47,測試版為 -0.92。該公司的債務與權益比率為 0.34,流動比率為 12.15,快速比率為 12.15。米特琳有限公司的 1 年低點為 0.30 美元,1 年高點為 0.68 美元。該業務的 50 日移動平均價為 0.43 美元,200 日移動平均價為 0.45 美元。

Get
取得
Metacrine
米塔克林
alerts:
警報:

Metacrine (NASDAQ:MTCR – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). Research analysts predict that Metacrine, Inc. will post -0.62 EPS for the current fiscal year.

甲基林(NASDAQ:MTCR-獲取評分)最後一次發布了其收益結果,日期為 11 月 14 日(星期一)。該公司報告了本季度每股盈利(0.13 美元),缺少分析師的共識估計為(0.11 美元)(0.02 美元)。研究分析師預測,Metacrine 公司將在本財政年度公佈 -0.62 每股盈利。

Analysts Set New Price Targets

分析師設定新的價格目標

Separately, HC Wainwright restated a "neutral" rating on shares of Metacrine in a research report on Wednesday, November 16th.
此外,HC 溫賴特在 11 月 16 日(星期三)的一份研究報告中重申了對米特琳股票的「中性」評級。

Institutional Inflows and Outflows

機構流入和流出

Institutional investors have recently modified their holdings of the stock. State Street Corp increased its holdings in shares of Metacrine by 482.8% in the second quarter. State Street Corp now owns 72,186 shares of the company's stock valued at $36,000 after buying an additional 59,800 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of Metacrine by 112.5% in the third quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock valued at $66,000 after buying an additional 72,306 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Metacrine in the third quarter valued at $84,000. Bank of New York Mellon Corp bought a new position in shares of Metacrine in the first quarter valued at $126,000. Finally, Bank of America Corp DE increased its holdings in shares of Metacrine by 10.5% in the first quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after buying an additional 24,964 shares in the last quarter. Institutional investors own 34.28% of the company's stock.

機構投資者最近修改了股票的持有量。國街公司在第二季度增加了其對梅特克林股份的持有量 482.8%。州街公司現在擁有該公司的 72,186 股股份,價值 36,000 美元,在上一季度額外購買 59,800 股股票後。城堡顧問有限責任公司在第三季度將其在 Metacrine 股份的持有量增加了 112.5%。城堡顧問有限責任公司現在擁有該公司股票的 136,606 股,價值為 66,000 美元,在上個季度購買了額外的 72,306 股之後。簡街集團有限責任公司在第三季度購買了梅特克林股份的新頭寸,價值為 84,000 美元。紐約梅隆銀行在第一季度買入了價值 126,000 美元的 Metacrine 股份的新頭寸。最後,美國銀行公司 DE 在第一季度增加了其對梅塔克林股份的持有量 10.5%。美國銀行股份有限公司在上一季度額外購買了 24,964 股股票後,現在擁有該公司股票 263,340 股,價值為 161,000 美元。機構投資者擁有公司 34.28% 的股票。

Metacrine Company Profile

梅特克林公司簡介

(Get Rating)

(取得評分)

Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.

Metacrine, Inc 是一家臨床階段生物製藥公司,致力於發現和開發針對胃腸疾病患者的療法。它正在開發 MET642,該試驗已完成治療潰瘍性結腸炎的 I 期臨床試驗。梅塔克林公司成立於 2014 年,總部位於加利福尼亞州聖地牙哥。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on Metacrine (MTCR)
  • Is Seagate Technology Signaling the End of its Normalization?
  • eHealth Stock Rises from the Ashes. Time to Get In?
  • Can Yext A.I. Search Platform Drive Growth in 2023?
  • Cassava Sciences Stock Undervalued with Its $124 Price Target?
  • Constellation Brands: Are Consumers Trading Down for Rail Drinks?
  • 獲取有關二甲基林(MTCR)的研究報告的免費副本
  • 希捷技術是否表示其正常化的結束?
  • 醫健通股票從灰燼中升起。是時候進去了嗎?
  • Yext 人工智能搜尋平台能在 2023 年推動增長嗎?
  • 木薯科學股票被低估,其 124 美元的目標價格?
  • 星座品牌:消費者是否會因鐵路飲料而下跌?

Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.

接收梅塔克林日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Metacrine 及相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論